Acylated active agents and methods of their use for the treatment of autoimmune disorders
Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
1. A method of modulating an autoimmunity marker in a subject, the method comprising administering to the subject an effective amount of a compound of the structure:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the autoimmunity marker is for ulcerative colitis or Crohn's disease.
3. The method of claim 1 , wherein a CYP1A1 mRNA level, intestinal motility, CD4 + CD25 + Treg cell count, short chain fatty acids level, or mucus secretion is increased following the administration of the compound to the subject; or
wherein abdominal pain, gastrointestinal inflammation, gastrointestinal permeability, gastrointestinal bleeding, intestinal motility, or frequency of bowel movements is reduced following the administration of the compound to the subject; or
wherein an interleukin-8 (IL-8) level, macrophage inflammatory protein 1α (MIP-1α) level, macrophage inflammatory protein 1β (MIP-1β) level, NFκB level, inducible nitric oxide synthase (iNOS) level, matrix metallopeptidase 9 (MMP9) level, interferon γ (IFNγ) level, interleukin-17 (IL17) level, intercellular adhesion molecule (ICAM) level, CXCL13 level, 8-iso-prostaglandin F 2α (8-iso-PGF2α) level IgA level, calprotectin level, lipocalin-2 level, or indoxyl sulfate level is reduced following the administration of the compound to the subject; or
wherein the T h 1 cell count is modulated following the administration of the compound to the subject.
4. The method of claim 1 , wherein the method comprises administering the compound to the subject orally.
5. A method of treating an autoimmune disorder in a subject suffering from the autoimmune disorder, the method comprising administering to the subject an effective amount a compound of the structure:
or a pharmaceutically acceptable salt thereof.
6. The method of claim 5 , wherein the autoimmune disorder is ulcerative colitis.
7. The method of claim 5 , wherein the autoimmune disorder is Crohn's disease.
8. The method of claim 5 , wherein a CYP1A1 mRNA level, intestinal motility, CD4 + CD25 + Treg cell count, short chain fatty acids level, or mucus secretion is increased following the administration of the compound to the subject; or
wherein abdominal pain, gastrointestinal inflammation, gastrointestinal permeability, gastrointestinal bleeding, intestinal motility, or frequency of bowel movements is reduced following the administration of the compound to the subject; or
wherein an interleukin-8 (IL-8) level, macrophage inflammatory protein 1α (MIP-1α) level, macrophage inflammatory protein 1 β (MIP-1β) level, NFκB level, inducible nitric oxide synthase (iNOS) level, matrix metallopeptidase 9 (MMP9) level, interferon γ (IFNγ) level, interleukin-17 (IL17) level, intercellular adhesion molecule (ICAM) level, CXCL13 level, 8-iso-prostaglandin F 2α (8-iso-PGF2α) level IgA level, calprotectin level, lipocalin-2 level, or indoxyl sulfate level is reduced following the administration of the compound to the subject; or
wherein the T h 1 cell count is modulated following the administration of the compound to the subject.
9. The method of claim 5 , wherein the method comprises administering the compound to the subject orally.